CARDIOTOXICIDAD POR QUIMIOTERAPIA PDF

Download Citation on ResearchGate | On Dec 1, , Edwin Arévalo Guerrero and others published Rol del strain miocárdico en. Abstract. RUIZ-MORI, Enrique; AYALA-BUSTAMANTE, Leonor; BURGOS- BUSTAMANTE, Jorge and PACHECO ROMAN, Cristian. Chemotherapy-induced . Resumen. RUIZ-MORI, Enrique; AYALA-BUSTAMANTE, Leonor; BURGOS- BUSTAMANTE, Jorge y PACHECO ROMAN, Cristian. Chemotherapy-induced.

Author: Kajijar Keshura
Country: Singapore
Language: English (Spanish)
Genre: Love
Published (Last): 23 October 2006
Pages: 139
PDF File Size: 11.66 Mb
ePub File Size: 10.28 Mb
ISBN: 709-5-84971-127-4
Downloads: 10274
Price: Free* [*Free Regsitration Required]
Uploader: Guzahn

Outros sinais observados incluem edema de membros inferiores, hepatomegalia, ascite e taquicardia.

No entanto, poucos ensaios avaliaram o uso do BNP como screeening inicial Na Tabela 5sugerimos monitoramento por eletrocardiograma ECG.

No entanto, alguns estudos merecem destaque pelos seus achados. O paclitaxel interfere com a via CYP2C8, envolvida no metabolismo da sinvastatina. Entretanto, casos de torsades de pointes foram descritos em pacientes com hipocalemia ou hipomagnesemia As vantagens do ultrassom Doppler incluem: Os dados do mesmo estudo de Walker et al. A cardiotoxicidade da ciclofosfamida pode apresentar-se de forma aguda ou subaguda 4.

A maior parte dos pacientes que desenvolveu HAS durante o tratamento foi tratada com anti-hipertensivos e a terapia com trastuzumabe foi mantida. Recentemente, o estudo experimental de Casini S. Apresentam atividade antitumoral significativa contra o carcinoma do colo uterino, linfomas e tumores testiculares 4.

Recomenda-se manter o paciente em normovolemia e utilizar com cautela anti-hipertensivos durante o tratamento com o bortezomibe. Ocorre o espessamento fibroso da valvas, sendo mais comprometidas as do lado esquerdo. Aspectos fundamentais que devem ser considerados no manejo desses pacientes: Cardiotoxicity of anticancer cardiotoxixidad Cardiac side-effects of cancer chemotherapy.

Cardiovascular complications of cancer therapy: Cardiotoxicity of anticancer drugs: J Natl Cancer Inst. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: Am J Clin Pathol. J Am Coll Cardiol. More ‘malignant’ than cancer? Five-year survival following a first admission for heart carduotoxicidad. Eur J Heart Fail. Singal PK, Iliskovic N.

N Engl J Med. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.

[Anthracycline-induced cardiotoxicity: report of fatal cases].

Cardiac dysfunction in the trastuzumab clinical trials experience. Reversibility of left ventricular dysfunction resulting from chemotherapy: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

  GUTHRIE GOVAN FIVES TAB PDF

Anticancer therapy induced cardiotoxicity: Detection of anthracycline-induced cardiotoxicity. Li T, Singal PK. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Dexrazoxane in the prevention of cardiotoxicidxd cardiotoxicity.

Early diagnosis of chemotherapy-induced cardiomyopathy: Cardiotoxicixad of cytotoxic drugs. Type II chemotherapy-related cardiac dysfunction: Risk of cardiac dysfunction with trastuzumab in breast cancer patients: Requirement for neuregulin receptor erbB2 in neural and cardiac development.

ErbB2 is essential in the prevention of dilated cardiomyopathy. Herceptin and the heart – a molecular modifier of cardiac failure. Serum HER2 levels are increased in patients with chronic heart failure.

Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Medina PJ, Goodin S. Cardiac safety of lapatinib: Cardiotoxicity of chemotherapeutic agents: Recent advances in breast cancer radiotherapy: Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Radiation dose-volume effects in the heart.

Cardiovascular toxicity caused by cancer treatment: The diagnosis and management of cardiovascular disease in cancer patients. Early and late arrhythmogenic effects of doxorubicin. Nat Clin Pract Oncol. Cardinale D, Sandri Quimioteraipa.

I Diretriz Brasileira de Cardio-Oncologia da Sociedade Brasileira de Cardiologia

Role of biomarkers in chemotherapy-induced cardiotoxicity. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Superior detection of cardiotoxicity during chemotherapy using biomarkers.

Identification of anthracycline cardiotoxicity: J Am Soc Echocardiogr.

EBSCOhost | | Cardiotoxicidad inducida por quimioterapia.

Atrial fibrillation after thoracic surgery for lung cancer: Utility of prechemotherapy echocardiographical assessment of cardiac abnormalities. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Soc Echocardiog. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson. Mechanisms of anthracycline cardiac injury: Guidelines for cardiac monitoring of children during and after anthracycline cadiotoxicidad Guidelines for clinical use of cardiac radionuclide imaging.

Congestive heart cardiohoxicidad and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.

  HONGOS BIOLUMINISCENTES PDF

Management of cardiac health in trastuzumab-treated patients with breast cancer: Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. Cardioprotective interventions for cancer patients receiving anthracyclines.

Cochrane Database Syst Rev. Doxorubicin-induced congestive heart failure in adults. Response of doxorubicin-induced cardiomyopathy to the current management quiimioterapia of heart failure.

J Heart Lung Transplant.

Cardiotoxicidad inducida por quimioterapia.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and quimiotegapia heart failure.

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.

Results of the survival and ventricular enlargement trial. Goldstein S, Hjalmarson A. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: Curr Control Trials Cardiovasc Med. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. Cardiotoxicldad Heart Failure Study Group. Effect of carvedilol on survival in severe chronic heart failure. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure.